Clovis Close To Bankruptcy As Cancer Drug Outlook Worsens
Rubraca Revenues Are Shrinking
Executive Summary
Troubles are mounting for Clovis and its PARP inhibitor Rubraca, and now the company looks to be just months from bankruptcy.
You may also be interested in...
Can Lynparza Hold On As PARP Inhibitors Enter First-Line Prostate Cancer Market?
AstraZeneca, Pfizer and Johnson & Johnson are presenting Phase III data for PARP inhibitors combined with anti-androgen drugs in first-line mCRPC, a potential blockbuster opportunity.
Stock Watch: Post-Pandemic Drug Commercialization Shifts
Emerging from the pandemic after nearly three years, therapy areas and drug classes are traveling at different speeds.
The Top Five Pharma Stories Of 2022
Scrip has taken a look back at five of the biggest story themes in no particular order of 2022 where once again the biopharma industry had plenty on its plate.